TGX-221

• Description :

  TGX-221 is a potent, selective, and cell membrane permeable inhibitor of the PI3K p110β catalytic subunit, used for cancer treatment.

• UNSPSC :

  12352005

• Hazard Statement :

  H302

• Target :

  PI3K

• Type :

  Reference compound

• Related Pathways :

  PI3K/Akt/mTOR

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/TGX-221.html

• Purity :

  99.74

• Solubility :

  DMSO : 12.5 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  O=C1N2C(C(C(NC3=CC=CC=C3)C)=CC(C)=C2)=NC(N4CCOCC4)=C1

• Molecular Formula :

  C21H24N4O2

• Molecular Weight :

  364.44

• Precautions :

  H302

• References & Citations :

  [1]Zhao Y, et al. Prodrug strategy for PSMA-targeted delivery of TGX-221 to prostate cancer cells. Mol Pharm. 2012 Jun 4;9 (6) :1705-16.|[2]Ge Q, et al. The phosphoinositide 3'-kinase p110δ modulates contractile protein production and IL-6 release in human airway smooth muscle. J Cell Physiol. 2012 Aug;227 (8) :3044-52.|[3]Müller KM, et al. Role of protein kinase C and epidermal growth factor receptor signalling in growth stimulation by neurotensin in colon carcinoma cells. BMC Cancer. 2011 Oct 2;11:421.|[4]Sturgeon SA, et al. Advantages of a selective beta-isoform phosphoinositide 3-kinase antagonist, an anti-thrombotic agent devoid of other cardiovascular actions in the rat. Eur J Pharmacol. 2008 Jun 10;587 (1-3) :209-15.|[5]Chaussade C, et al. Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling. Biochem J. 2007 Jun 15;404 (3) :449-58.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  PI3Kβ; PI3Kδ

• CAS Number :

  [663619-89-4]